10/17/2023
As ViewRay end on Oct 25th we will keep our MRIdian online , but we will be holding off on routinely adding new patients to our list to treat on the unit. For now I will continue using MR based planning and focal dose escalation to dominate lesions using our state of the art Edge or Halcyon units. I remain happy to consult any patients either in person or by telehealth who are looking for guidance on their treatment for prostate cancer with advanced radiotherapy.
As the principle Investigator, I am looking forward to having our data presented for outcomes in the Co-primary endpoint for GU toxicity from NRG GU-005 Phase III international trial for SBRT vs IMRT with Advanced Imade Guidance next year hopefully at ASTRO. We hope to confirm a meaningful improvement in EPIC GU quality of life scores at two years post SBRT of 36.25 Gy. I truly believe most patients can be safely and equivalently treated with SBRT if appropriately selected and planned. The PACE-B Phase III study on Cyberknife recently showed equivalently for bDFS at 5 years at 95 vs 96%. NRG GU-005 allowed all platforms including being the first study to allow MR Linac for SBRT for intermediate risk prostate cancer. Hopefully the combination of MR based planning, along with advanced image guidance will prove to find both improved GU toxicity at 2 years along with improved disease free survival at 5 years. I continue to treat all of my patients per the GU-005 protocols high quality treatment standard, in addition to offering focal dose escalation to the dominate lesions to a minimal dose of 8 Gy per fraction to a minimal dose of 40 Gy.
